Daiichi Sankyo. has filed a patent for an antibody-drug conjugate for treating cancer. The conjugate links an anti-HER2 antibody to an antitumor compound via a specific linker structure. The method involves administering the conjugate to individuals with cancer for improved therapeutic effects. GlobalData’s report on Daiichi Sankyo gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Daiichi Sankyo Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Daiichi Sankyo, Cancer treatment biomarkers was a key innovation area identified from patents. Daiichi Sankyo's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Antibody-drug conjugate for treating cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Daiichi Sankyo Co Ltd

A recently filed patent (Publication Number: US20240026030A1) outlines a method for treating cancer in individuals by administering a drug containing an antibody-drug conjugate or a salt thereof. The conjugate includes a linker, an antitumor compound, and an anti-HER2 antibody connected to the linker. The patent specifies the structure of the antibody-drug conjugate and the amino acid sequences of the heavy and light chains of the anti-HER2 antibody, providing detailed information on the components used in the treatment method.

Furthermore, the patent details the average number of units of the drug-linker structure conjugated per antibody in the antibody-drug conjugate, ranging from 2 to 8 units. The method described in the patent involves administering a pharmaceutical composition containing the antibody-drug conjugate as an active component along with a pharmaceutically acceptable formulation component. The patent emphasizes the specific structure and composition of the antibody-drug conjugate, highlighting the importance of the anti-HER2 antibody and the linker in the treatment of cancer in individuals.

To know more about GlobalData’s detailed insights on Daiichi Sankyo, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies